Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
2024年2月29日 - 3:22PM
ビジネスワイヤ(英語)
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a
clinical-stage biopharmaceutical company developing a broad
pipeline of novel immunotherapies by applying its proprietary
technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor
Activated Immunomodulator (TRACIr) platforms, today announced the
pricing of an underwritten public offering of 4,440,851 shares of
its common stock at a public offering price of $46.50 per share and
pre-funded warrants to purchase 1,935,483 shares of common stock at
a price of $46.499 per pre-funded warrant, which represents the per
share price for the common stock less the $0.001 per share exercise
price for each such pre-funded warrant. The aggregate gross
proceeds to Janux from the offering, before deducting underwriting
discounts and commissions and other estimated offering expenses and
excluding the exercise of any pre-funded warrants, are expected to
be approximately $296.5 million. In addition, Janux has granted the
underwriters a 30-day option to purchase up to an additional
956,450 shares of its common stock. All of the shares to be sold in
the offering are to be sold by Janux. The offering is expected to
close on or about March 4, 2024, subject to customary closing
conditions.
BofA Securities, TD Cowen, Cantor Fitzgerald & Co. and
William Blair & Company, L.L.C. are acting as joint
book-running managers for the offering. BTIG, LLC and Wedbush
PacGrow are acting as the lead managers for the offering.
The Company intends to use the net proceeds from the offering to
advance clinical development of its internal product pipeline and
for general corporate purposes.
The securities are being offered by the company pursuant to a
Registration Statement on Form S-3 previously filed and declared
effective by the Securities and Exchange Commission (SEC). A
preliminary prospectus supplement and accompanying prospectus
relating to the offering has been filed, and a final prospectus
supplement and accompanying prospectus relating to the offering
will be filed with the SEC and will be available on the SEC’s
website, located at www.sec.gov. Copies of the final prospectus
supplement and the accompanying prospectus relating to this
offering may be obtained, when available, from BofA Securities,
NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina
28255-0001, Attention: Prospectus Department, or by email at
dg.prospectus_requests@bofa.com; Cowen and Company, LLC, 599
Lexington Avenue, New York, NY 10022, by email at
Prospectus_ECM@cowen.com or by telephone at (833) 297-2926; Cantor
Fitzgerald & Co., Attention: Capital Markets, 110 East 59th
Street, 6th Floor, New York, NY 10022, or by email at
prospectus@cantor.com; or William Blair & Company, L.L.C.,
Attention: Prospectus Department, 150 North Riverside Plaza,
Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email
at prospectus@williamblair.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Janux Therapeutics, Inc.
Janux is a clinical-stage biopharmaceutical company developing
tumor-activated immunotherapies for cancer. Janux’s proprietary
technology enabled the development of two distinct bispecific
platforms: TRACTr and TRACIr. The goal of both platforms is to
provide cancer patients with safe and effective therapeutics that
direct and guide their immune system to eradicate tumors while
minimizing safety concerns. Janux is currently developing a broad
pipeline of TRACTr and TRACIr therapeutics directed at several
targets to treat solid tumors. Janux has two TRACTr therapeutic
candidates in clinical trials, the first targeting PSMA is in
development for prostate cancer, and the second targeting EGFR is
being developed for colorectal, lung, head and neck, and renal
cancers.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include statements
regarding, among other things, the timing, size, terms and
completion of the proposed public offering, the anticipated use of
proceeds therefrom and from the grant of the option to purchase
additional shares. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. These
forward-looking statements are based upon Janux’s current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results could differ materially
from those anticipated in such forward-looking statements as a
result of various risks and uncertainties, which include, without
limitation, risks and uncertainties associated with market
conditions, the satisfaction of customary closing conditions
related to the public offering, and the other risks described in
Janux’s filings with the SEC. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Janux undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240228758808/en/
Investors: Andy Meyer Janux Therapeutics ameyer@januxrx.com
(202) 215-2579
Media: Jessica Yingling, Ph.D. Little Dog Communications Inc.
jessica@litldog.com (858) 344-8091
Janux Therapeutics (NASDAQ:JANX)
過去 株価チャート
から 4 2024 まで 5 2024
Janux Therapeutics (NASDAQ:JANX)
過去 株価チャート
から 5 2023 まで 5 2024